The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | IsaVCd and IsaR maintenance in newly diagnosed myeloma with severe renal impairment
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, the EAE116 study (NCT05147493) evaluating isatuximab, bortezomib and cyclophosphamide (IsaVCd) and isatuximab plus lenalidomide (IsaR) maintenance in newly diagnosed multiple myeloma patients severe renal impairment. He highlights the regimen’s efficacy and tolerability, alongside the importance of prompt supportive care and early anti-myeloma treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
